New CAR-T therapy targets Hard-to-Treat cancers
NCT ID NCT07181720
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells that have a protein called CD70, and infusing them back into the body. The main goals are to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD70-targeted CAR-T cells
What this could lead to
If successful, this could provide a new treatment option for patients with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 90 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 901 Hospital of Joint Logistics Support Force of People Liberation Army
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact